Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1884 1
1895 1
1899 1
1906 1
1912 1
1917 1
1935 1
1936 1
1947 2
1948 5
1949 1
1950 2
1951 1
1952 1
1954 3
1960 1
1965 1
1966 2
1967 5
1968 5
1969 6
1970 7
1971 4
1972 10
1973 12
1974 10
1975 10
1976 15
1977 15
1978 14
1979 8
1980 16
1981 19
1982 23
1983 17
1984 24
1985 29
1986 29
1987 30
1988 29
1989 31
1990 32
1991 26
1992 32
1993 47
1994 40
1995 30
1996 37
1997 40
1998 52
1999 42
2000 30
2001 44
2002 34
2003 35
2004 35
2005 45
2006 45
2007 39
2008 40
2009 39
2010 44
2011 43
2012 41
2013 57
2014 47
2015 49
2016 58
2017 68
2018 67
2019 73
2020 83
2021 109
2022 85
2023 87
2024 103
2025 101
2026 56

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,157 results

Results by year

Filters applied: . Clear all
Page 1
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. Among authors: howell sj. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Free PMC article. Clinical Trial.
Reply.
Ayyash K, Howell SJ, McGinigle KL. Ayyash K, et al. Among authors: howell sj. J Vasc Surg. 2024 Apr;79(4):986-987. doi: 10.1016/j.jvs.2023.11.063. J Vasc Surg. 2024. PMID: 38519221 Free article. No abstract available.
Polygenic risk scores and breast cancer risk prediction.
Roberts E, Howell S, Evans DG. Roberts E, et al. Among authors: howell s. Breast. 2023 Feb;67:71-77. doi: 10.1016/j.breast.2023.01.003. Epub 2023 Jan 10. Breast. 2023. PMID: 36646003 Free PMC article. Review.
Tamoxifen evolution.
Howell A, Howell SJ. Howell A, et al. Among authors: howell sj. Br J Cancer. 2023 Feb;128(3):421-425. doi: 10.1038/s41416-023-02158-5. Epub 2023 Feb 10. Br J Cancer. 2023. PMID: 36765172 Free PMC article. Review. No abstract available.
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.
Rugo HS, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Jhaveri KL, Krivorotko P, Loibl S, Morales Murillo S, Nowecki Z, Okera M, Park YH, Sohn J, Toi M, Iwata H, Yousef S, Zhukova L, Logan J, Twomey K, Khatun M, D'Cruz CM, Turner NC. Rugo HS, et al. Among authors: howell sj. ESMO Open. 2024 Sep;9(9):103697. doi: 10.1016/j.esmoop.2024.103697. Epub 2024 Sep 5. ESMO Open. 2024. PMID: 39241495 Free PMC article. Clinical Trial.
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
Oliveira M, Rugo HS, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Toi M, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Nowecki Z, Park YH, Sohn JH, Tokunaga E, Yousef S, Zhukova L, Fulford M, Andrews H, Wadsworth I, D'Cruz C, Turner NC; CAPItello-291 study group. Oliveira M, et al. Among authors: howell sj. Lancet Oncol. 2024 Sep;25(9):1231-1244. doi: 10.1016/S1470-2045(24)00373-5. Lancet Oncol. 2024. PMID: 39214106 Clinical Trial.
Editorial Comment.
Howell SM, Benson CR. Howell SM, et al. J Urol. 2024 Mar;211(3):463-464. doi: 10.1097/JU.0000000000003826.01. Epub 2024 Jan 10. J Urol. 2024. PMID: 38198587 No abstract available.
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton C, Hughes DA, Williamson P, Baker GA, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE; SANAD II collaborators. Marson A, et al. Among authors: howell s. Lancet. 2021 Apr 10;397(10282):1363-1374. doi: 10.1016/S0140-6736(21)00247-6. Lancet. 2021. PMID: 33838757 Free PMC article. Clinical Trial.
2,157 results